Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 25/100

aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR

Key Takeaway: aTyr Pharma, Inc. is currently under a class action lawsuit for violating securities laws, specifically regarding misleading statements about its drug candidate Efzofitimod. Investors allege that the company provided overly optimistic claims regarding the drug's efficacy in reducing steroid usage among patients. The class period for affected shareholders runs from January 16, 2025, to September 12, 2025, with a deadline for participation in the case set for December 8, 2025. The DJS Law Group is actively seeking shareholders who may have experienced financial losses during this period.

Market Sentiment Analysis

CONCERNS & RISKS

  • aTyr Pharma is facing a class action lawsuit for securities law violations.
  • Investors were misled about the drug Efzofitimod's effectiveness.
  • False statements about the potential to taper steroid use were made to the market.
  • Shareholders who purchased during the class period may have suffered financial losses.

Full Press Release Details

LOS ANGELES, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: January 16, 2025 to September 12, 2025
DEADLINE: December 8, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. aTyr was overwhelmingly positive in its statements to the market about the efficacy of its drug candidate, Efzofitimod. The Company misled investors about the drug’s potential to help patients completely taper the usage of steroids. Based on these facts, aTyr’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What lawsuit is DJS Law Group involved in?

DJS Law Group is involved in a class action lawsuit against aTyr Pharma for securities violations.

What was aTyr Pharma accused of?

aTyr Pharma is accused of making false claims about its drug candidate Efzofitimod.

What is the deadline for shareholders to act?

The deadline for shareholders to participate is December 8, 2025.

Who can join the class action?

Shareholders who purchased ATYR shares between January 16 and September 12, 2025, can join.

Is there any cost to participate in the case?

There is no cost or obligation for shareholders to participate in the case.

Last updated: Dec 2, 2025